Business Description
Biophytis SA
ISIN : FR001400OLP5
Compare
Compare
Traded in other countries / regions
ALBPS.France6XB3.GermanyBPTSY.USA0D1W.UK IPO Date
2018-07-17Description
Biophytis SA is a France-based biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases. Its drug candidate BIO101, is an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and DMD.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.32 | |||||
| Equity-to-Asset | -0.73 | |||||
| Debt-to-Equity | -1.13 | |||||
| Debt-to-EBITDA | -0.54 | |||||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 59.1 | |||||
| 3-Year EPS without NRI Growth Rate | 52.8 | |||||
| 3-Year FCF Growth Rate | 47.4 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 44.78 | |||||
| 9-Day RSI | 43.71 | |||||
| 14-Day RSI | 41.42 | |||||
| 6-1 Month Momentum % | -58.03 | |||||
| 12-1 Month Momentum % | -86.67 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.41 | |||||
| Quick Ratio | 0.41 | |||||
| Cash Ratio | 0.16 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -117.8 | |||||
| Shareholder Yield % | 38.81 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROA % | -128.15 | |||||
| ROIC % | -102.96 | |||||
| 3-Year ROIIC % | 4.94 | |||||
| ROC (Joel Greenblatt) % | -3555.06 | |||||
| ROCE % | -1426.32 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -0.46 | |||||
| EV-to-Forward-EBIT | -0.11 | |||||
| EV-to-EBITDA | -0.49 | |||||
| EV-to-Forward-EBITDA | -0.11 | |||||
| EV-to-Forward-Revenue | 0.33 | |||||
| EV-to-FCF | -0.61 | |||||
| Earnings Yield (Greenblatt) % | -213.29 | |||||
| FCF Yield % | -651.67 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Biophytis SA Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -5.221 | ||
| Beta | 0.57 | ||
| Volatility % | 44.45 | ||
| 14-Day RSI | 41.42 | ||
| 14-Day ATR (€) | 0.019035 | ||
| 20-Day SMA (€) | 0.30605 | ||
| 12-1 Month Momentum % | -86.67 | ||
| 52-Week Range (€) | 0.28 - 4.08 | ||
| Shares Outstanding (Mil) | 5.24 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Biophytis SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Biophytis SA Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Biophytis SA Frequently Asked Questions
What is Biophytis SA(FRA:6XB3)'s stock price today?
The current price of FRA:6XB3 is €0.30. The 52 week high of FRA:6XB3 is €4.08 and 52 week low is €0.28.
When is next earnings date of Biophytis SA(FRA:6XB3)?
The next earnings date of Biophytis SA(FRA:6XB3) is .
Does Biophytis SA(FRA:6XB3) pay dividends? If so, how much?
Biophytis SA(FRA:6XB3) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers